PALISADE BIO, INC.
PALIOther · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $250,000 | $0 | — | $13,520 |
| Operating income | −$18.1M | −$14.9M | −$13.1M | −$15.7M | −$41.9M | −$10.7M |
| Net income | −$16.8M | −$14.4M | −$12.3M | −$14.3M | −$26.6M | −$16.3M |
| Total assets | $134.3M | $10.9M | $14.1M | $15.8M | $12.5M | $13.0M |
| Total liabilities | $5.0M | $3.4M | $2.7M | $3.3M | $5.1M | $3.3M |
| Equity | $129.4M | $7.5M | $11.3M | $12.5M | $7.4M | $9.8M |
| EPS (diluted) | $-0.30 | $-10.19 | $-27.01 | $-16.53 | $-169.74 | $-3.72 |
| Shares out. | 4.4M | 12.8M | 4.5M | 18.2M | 17.3M | 9.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −13.0%
- Return on assets
- −12.5%
- Return on capital (ROCE)
- −13.9%
- Liabilities / assets
- 3.7%
- Debt / equity
- 0.04×
- Book value / share
- $29.43
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −4.4%clean
- Piotroski F-Score
- 5/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 16, 2021
- NT 10-Qmissed a reporting deadline ↗Aug 9, 2016
- NT 10-Kmissed a reporting deadline ↗Mar 15, 2012
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Soleus Capital Master Fund, L.P.Passive (13G)May 27, 2026
- Commodore Capital LpPassive (13G)May 15, 2026
- Ra Capital Management, L.P.Passive (13G)May 15, 2026
- Perceptive Advisors LlcPassive (13G)May 15, 2026
- Ameriprise Financial IncPassive (13G)May 15, 2026
- Point72 Asset Management, L.P.Passive (13G)May 15, 2026
- Squadron Capital Management LlcPassive (13G)Feb 17, 2026
- Deep Track Capital, LpPassive (13G)Feb 13, 2026
- Octagon Capital Advisors LpPassive (13G)Feb 10, 2026
- Franklin Resources IncPassive (13G)Jan 29, 2026
- Janus Henderson Group PlcPassive (13G)Dec 8, 2025
- Armistice Capital, LlcPassive (13G)Aug 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Jones Mitchell LawrenceOfficer — Chief Medical Officer | Feb 11, 2026 | Option exercise | 8,000 | — |
| Finley John DavidOfficer — CEO, CFO | Feb 11, 2026 | Option exercise | 13,333 | — |
| Williams Donald AllenDirector | Jan 16, 2026 | Buy | 5,000 | $1.67 |
| Williams Donald AllenDirector | Jan 9, 2026 | Buy | 5,000 | $1.88 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 26.9M | 10.4 | +3.0% |
| Apr 30, 2026 | 26.1M | 5.2 | +2.0% |
| Apr 15, 2026 | 25.6M | 7.0 | -0.5% |
| Mar 31, 2026 | 25.8M | 5.4 | -1.5% |
| Mar 13, 2026 | 26.2M | 8.8 | -2.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 12, 2026
- Other material eventApr 2, 2026
- Amended charter or bylaws · Shareholder voteDec 4, 2025
- Director / officer changeOct 22, 2025
- Shareholder voteOct 20, 2025
- Other material eventOct 16, 2025
- Other material eventOct 9, 2025
- Other material eventSep 26, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13GMay 27, 2026
- EFFECTMay 21, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13GMay 15, 2026
- S-3May 12, 2026
- 8-KMay 12, 2026
- 10-QMay 12, 2026
- ARSApr 29, 2026
- DEFA14AApr 29, 2026
- DEF 14AApr 29, 2026
- PRE 14AApr 17, 2026
- 8-KApr 2, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.